Skip to main content

Table 1 Co-stimulation of molecular expression on B-ALL cells (%)

From: Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells

Number Patient ID CD80 CD80 (Ara-C) CD86 CD86 (Ara-C)
1 149290 5.48 12.84 5.20 12.49
2 152618 4.56 5.30 5.81 7.21
3 143674 8.71 9.55 41.77 59.73
4 146937 2.69 10.30 10.45 20.39
5 137930 4.98 13.86 4.37 31.86
6 153776 4.15 9.55 4.25 16.41
7 153832 7.21 7.17 24.05 27.81
8 154438 2.34 2.75 1.72 3.11
9 154915 3.94 8.27 4.32 15.12
10 161080 0.61 1.04 3.01 5.12
11 164302 1.02 1.32 0.31 0.44
12 151732 0.81 1.32 16.51 17.55
13 161015 3.73 33.65 16.02 47.75
14 160483 9.96 10.86 2.93 3.45
15 161101 5.27 5.73 17.53 43.26
16 141322 5.25 12.90 6.60 9.07
17 178545 3.01 4.41 3.97 6.04
18 172540 9.87 10.1 11.70 13.66
19 173869 3.68 3.38 9.48 11.95
20 175981 4.57 5.65 0.42 1.65
21 153971 4.48 17.44 0.44 24.83